| ID Source | ID |
|---|---|
| PubMed CID | 14743 |
| CHEMBL ID | 2356993 |
| CHEBI ID | 35002 |
| SCHEMBL ID | 940358 |
| MeSH ID | M0108644 |
| Synonym |
|---|
| 8gn84gwx51 , |
| unii-8gn84gwx51 |
| nsc26643 |
| testosterone phenpropionate |
| 1255-49-8 |
| testosterone 17-phenylpropionate |
| retandrol |
| testosterone, hydrocinnamate |
| testosterone phenylpropionate |
| nsc-26643 |
| testolent |
| 17beta-hydroxyandrost-4-en-3-one 3-phenylpropionate |
| androst-4-en-3-one, 17-(1-oxo-3-phenylpropoxy)-, (17-beta)- |
| nsc 26643 |
| androst-4-en-3-one, 17-(1-oxo-3-phenylpropoxy)-, (17beta)- |
| einecs 215-014-4 |
| [(8r,9s,10r,13s,14s,17s)-10,13-dimethyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl] 3-phenylpropanoate |
| testosterone 17beta-phenpropionate |
| D08574 |
| testanon 50 (tn) |
| (8r,9s,10r,13s,14s,17s)-10,13-dimethyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl 3-phenylpropanoate |
| A805391 |
| tox21_113116 |
| cas-1255-49-8 |
| dtxcid8028638 |
| dtxsid5048712 , |
| testosterone phenylpropionate [who-dd] |
| testosterone phenylpropionate [mart.] |
| 3-oxoandrost-4-en-17.beta.-yl 3-phenylpropionate |
| 17.beta.-hydroxyandrost-4-en-3-one 3-phenylpropionate |
| testosterone phenyl propionate |
| AM84364 |
| androst-4-en-3-one, 17-(1-oxo-3-phenylpropoxy)-, (17?)- |
| AKOS015895428 |
| gtpl7628 |
| testosterone hydrocinnamate |
| SCHEMBL940358 |
| CHEBI:35002 , |
| HHSXYDOROIURIP-FEZCWRLCSA-N |
| androst-4-en-3-one, 17-(1-oxo-3-phenylpropoxy)-, (17.beta.)- |
| 3-oxoandrost-4-en-17-yl 3-phenylpropanoate # |
| FD12013 |
| 4-androsten-17beta-ol-3-one 17-phenylpropionate |
| W-108401 |
| AC-28714 |
| CHEMBL2356993 |
| testosterone 17-phenylpropionate, analytical standard |
| DS-5641 |
| Q27088964 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs." | ( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019) | 0.51 |
| Class | Description |
|---|---|
| steroid ester | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| TDP1 protein | Homo sapiens (human) | Potency | 10.8707 | 0.0008 | 11.3822 | 44.6684 | AID686978 |
| AR protein | Homo sapiens (human) | Potency | 0.0969 | 0.0002 | 21.2231 | 8,912.5098 | AID743035; AID743036; AID743040; AID743053; AID743063 |
| glucocorticoid receptor [Homo sapiens] | Homo sapiens (human) | Potency | 6.1645 | 0.0002 | 14.3764 | 60.0339 | AID720692 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 2.9541 | 0.0002 | 29.3054 | 16,493.5996 | AID743069; AID743075; AID743077; AID743078; AID743079; AID743080; AID743091 |
| cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a | Homo sapiens (human) | Potency | 0.0077 | 0.0017 | 23.8393 | 78.1014 | AID743083 |
| thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 27.4872 | 0.0003 | 23.4451 | 159.6830 | AID743065; AID743067 |
| Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 68.5896 | 0.0023 | 19.5956 | 74.0614 | AID651631 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 7 (46.67) | 18.7374 |
| 1990's | 2 (13.33) | 18.2507 |
| 2000's | 1 (6.67) | 29.6817 |
| 2010's | 3 (20.00) | 24.3611 |
| 2020's | 2 (13.33) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.82) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 2 (10.00%) | 5.53% |
| Reviews | 1 (5.00%) | 6.00% |
| Case Studies | 1 (5.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 16 (80.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||